Revanasiddappa, B. C.
In Vitro Antiurolithiatic Activity Of Ethanolic Extract Of Desmodium Triflorum - Vol. 56 (07) - Mumbai Indian Drug Manufacture's Association - IDMA 2019 - 76-79
The ethanolic extract of Desmodium triflorum (EEDT) was investigated for in vitro antiurolithiatic activity by using nucleation and aggregation methods. phytochemical screening was also undertaken to reveal the presence of alkaloids, flavonoids, reducing sugars and sterols in the sample. The In vitro studies showed that the ethanolic extract inhibits aggregation, nucleation and growth of calcium oxalate crystals. The extract exhibited inhibitory action in both nucleation and aggregation assays at significant level. The results of nucleation assay were found to be significant and showed inhibition (60.39%) compared to standard cystone drug (79.59%) and in aggregation assay also showed inhibition (70.89%) compared to cystone (79.22%) at 500μgm/ml concentration. The results clearly indicated that EEDT has the capacity to inhibit the crystal formation and aggregation.
PHARMACEUTICS
In Vitro Antiurolithiatic Activity Of Ethanolic Extract Of Desmodium Triflorum - Vol. 56 (07) - Mumbai Indian Drug Manufacture's Association - IDMA 2019 - 76-79
The ethanolic extract of Desmodium triflorum (EEDT) was investigated for in vitro antiurolithiatic activity by using nucleation and aggregation methods. phytochemical screening was also undertaken to reveal the presence of alkaloids, flavonoids, reducing sugars and sterols in the sample. The In vitro studies showed that the ethanolic extract inhibits aggregation, nucleation and growth of calcium oxalate crystals. The extract exhibited inhibitory action in both nucleation and aggregation assays at significant level. The results of nucleation assay were found to be significant and showed inhibition (60.39%) compared to standard cystone drug (79.59%) and in aggregation assay also showed inhibition (70.89%) compared to cystone (79.22%) at 500μgm/ml concentration. The results clearly indicated that EEDT has the capacity to inhibit the crystal formation and aggregation.
PHARMACEUTICS